In a novel analysis examining the economic implications of generic semaglutide entering the Canadian market, researchers predict that the anticipated price reductions of up to 70% will dramatically increase both the cost-effectiveness and health system affordability of therapy options for patients with type 2 diabetes and high cardiorenal risk.